Difference between revisions of "Fondaparinux (Arixtra)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Venous thromboembolism (VTE) medications" to "Category:Venous thromboembolism medications") |
m (Text replacement - "[[Media:" to "[[File:") |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Selectively binds to antithrombin III (AT-III) and augments its activity to specifically inhibit activated Factor Xa. The risk of developing thrombus is reduced via inhibition of thrombin, which converts fibrinogen to fibrin in the coagulation cascade.<ref name="insert">[[ | + | Class/mechanism: Selectively binds to antithrombin III (AT-III) and augments its activity to specifically inhibit activated Factor Xa. The risk of developing thrombus is reduced via inhibition of thrombin, which converts fibrinogen to fibrin in the coagulation cascade.<ref name="insert">[[File:Fondaparinux.pdf | Fondaparinux (Arixtra) package insert (locally hosted backup)]]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 7: | Line 7: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[[ | + | *[[File:Fondaparinux.pdf | Fondaparinux (Arixtra) package insert (locally hosted backup)]]<ref name="insert"></ref> |
*[http://www.uptodate.com/contents/fondaparinux-patient-drug-information Fondaparinux (Arixtra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/fondaparinux-patient-drug-information Fondaparinux (Arixtra) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/fondaparinux-patient-drug-information Fondaparinux (Arixtra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/fondaparinux-patient-drug-information Fondaparinux (Arixtra) patient drug information (UpToDate)]</ref> | ||
Revision as of 23:22, 19 September 2021
General information
Class/mechanism: Selectively binds to antithrombin III (AT-III) and augments its activity to specifically inhibit activated Factor Xa. The risk of developing thrombus is reduced via inhibition of thrombin, which converts fibrinogen to fibrin in the coagulation cascade.[1]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
- 12/07/2001: Initial FDA approval: prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in:
- patients undergoing hip fracture surgery;
- patients undergoing hip replacement surgery;
- patients undergoing knee replacement surgery.
Also known as
- Brand names: Arixtra, Quixidar